Chemotherapy – University of Chicago Medical Center – USA

Survival: 4.7 months
Toxicity Grade: 5
Treatments: Chemotherapy
Drugs: Gemzar
Country: United States
City/State/Province: Chicago, Illinois
Hospital: University of Chicago Medical Center
Journal: Link
Date: 2/2001


Patients: This Phase II study involved 17 patients with malignant mesothelioma.

Treatment: The treatment consisted of the chemotherapy drug, gemcitabine.

Toxicity: Two patients died without documentation of progressive disease and at least one of these deaths was considered related to drug toxicity and disease progression. In addition, grade 3-4 toxicities included hematologic, infection, dyspnea, edema, malaise/fatigue, cerebellar, cardiac dysrhythmia, and hyponatremia.

Results: There were no complete or partial responses and the median survival time was 4.7 months.

Correspondence: Hedy L. Kindler, MD

Get your free copy of
“Surviving Mesothelioma” Today!